<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546351</url>
  </required_header>
  <id_info>
    <org_study_id>SP0746</org_study_id>
    <secondary_id>2004-000551-42</secondary_id>
    <nct_id>NCT00546351</nct_id>
  </id_info>
  <brief_title>Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.</brief_title>
  <official_title>A Multi-center, Open-label, follow-on Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Including a Double-blind, Randomized Time Point Withdrawal Subtrial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial
      is to assess safety and tolerability of long-term exposure of lacosamide (previously referred
      to as SPM 927) in subjects with painful distal diabetic neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing the Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).</measure>
    <time_frame>From entry Visit 1 through end of treatment (approximately 6.5 years)</time_frame>
    <description>Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).</measure>
    <time_frame>From entry Visit 1 through end of treatment (approximately 6.5 years)</time_frame>
    <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:
Is fatal
Is life-threatening
Results in persistent or significant disability/incapacity
Requires inpatient hospitalization
Prolongs existing inpatient hospitalization
Is a congenital anomaly/birth defect
Is considered to be an important medical event. Such an event may not be immediately life threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definitions above</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Baseline Visit.</measure>
    <time_frame>Baseline</time_frame>
    <description>On the Likert Scale, 0 = no pain and 10 = worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Last Visit.</measure>
    <time_frame>Last Visit (approximately 2 years)</time_frame>
    <description>On the Likert Scale, 0 = no pain and 10 = worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Pain Score as Measured by a 100 mm Visual Analog Scale (VAS) at Baseline.</measure>
    <time_frame>Baseline</time_frame>
    <description>Visual Analog Scale (VAS) 0 mm = no pain and 100 mm = worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Pain Score as Measured by a 100 mm Visual Analogue Scale (VAS) at Last Visit.</measure>
    <time_frame>Last Visit (approximately 2 years)</time_frame>
    <description>On VAS 0 mm = no pain and 100 mm = worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change (PGIC) at Last Visit.</measure>
    <time_frame>Last Visit (approximately 2 years)</time_frame>
    <description>The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse [score of 1] to much better [score of 7]).
Reported results are presented as Better (sum of mildly, moderately, or much better), No Change, or Worse (sum of mildly, moderately, or much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Intensity at Last Visit.</measure>
    <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
    <description>0 = no pain and 10 = most intense pain sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sharpness at Last Visit.</measure>
    <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
    <description>0 = not sharp and 10 = most sharp sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Heat at Last Visit.</measure>
    <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
    <description>0 = not hot and 10 = the most hot sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Cold at Last Visit.</measure>
    <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
    <description>0 = not cold and 10 = the coldest sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Dullness at Last Visit.</measure>
    <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
    <description>0 = not dull and 10 = most dull sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Unpleasantness at Final Visit.</measure>
    <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
    <description>0 = not unpleasant and 10 = most unpleasant sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Surface Pain at Last Visit.</measure>
    <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
    <description>0 = no surface pain and 10 = most intense surface pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Deep Pain at Last Visit.</measure>
    <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
    <description>0 = no deep pain and 10 = most intense deep pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Itchiness at Final Visit.</measure>
    <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
    <description>0 = not itchy and 10 = most itchy sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sensitivity at Last Visit.</measure>
    <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
    <description>0 = not sensitive and 10 = most sensitive sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Pain Interference With Sleep (11-point Likert Scale) at Baseline.</measure>
    <time_frame>Baseline</time_frame>
    <description>0 = no interference with sleep and 10 = worst possible interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Pain Interference With Sleep (11-point Likert Scale) at Last Visit.</measure>
    <time_frame>Last Visit</time_frame>
    <description>0 = no interference with sleep and 10 = worst possible interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Pain Interference With Activity (11-point Likert Scale) at Baseline.</measure>
    <time_frame>Baseline</time_frame>
    <description>0 = no interference with activity and 10 = worst possible interference with activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Pain Interference With Activity (11-point Likert Scale) at Last Visit.</measure>
    <time_frame>Last Visit</time_frame>
    <description>0 = no interference with activity and 10 = worst possible interference with activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS) at Baseline.</measure>
    <time_frame>Baseline</time_frame>
    <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS) at Last Visit.</measure>
    <time_frame>Last Visit</time_frame>
    <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Baseline.</measure>
    <time_frame>Baseline</time_frame>
    <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Last Visit.</measure>
    <time_frame>Last Visit</time_frame>
    <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">621</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Lacosamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years</description>
    <arm_group_label>Lacosamide</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who completed Study SP743 (NCT00238524) or SP874 (NCT00350103) and, in the
             investigator's opinion, might benefit from long-term administration of SP746
             (NCT00546351). Exception: subjects who prematurely discontinued

          -  SP743 (NCT00238524) or SP874 (NCT00350103) due to lack of efficacy or due to
             intolerability to trial medication (after Visit 5but prior to entering the Maintenance
             Phase) may be eligible to participate in SP746 (NCT00546351), after consultation with
             the medical monitor

        Exclusion Criteria:

          -  Subject has clinically relevant ECG abnormalities, or a QTc interval ≥500 ms, and/or a
             QTc interval increase of ≥60 ms from the mean pre-dose QTc value at Visit 2 of SP743
             (NCT00238524) or SP874 (NCT00350103)

          -  Subject has aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥3
             times the upper limit of the normal range (ULN) with total bilirubin ≥2 times ULN or
             transaminases (AST and/or ALT) ≥5 times ULN

          -  Subject has a clinically relevant medical condition that, in the opinion of the
             investigator, jeopardizes or compromises the subject's ability to participate in this
             trial

          -  Subject is a pregnant or nursing female, or is of childbearing potential and is not
             surgically sterile, 2 years postmenopausal, or does not practice 2 combined methods of
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>180</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>183</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>003</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>006</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>002</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>001</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>005</name>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>004</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>011</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>014</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>017</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>019</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>012</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>013</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>015</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>016</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>210</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>010</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>028</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>220</name>
      <address>
        <city>Chomutov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>026</name>
      <address>
        <city>Litomerice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>027</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>024</name>
      <address>
        <city>Ostrava-Poruba</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>029</name>
      <address>
        <city>Pisek</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>021</name>
      <address>
        <city>Praha 1</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>022</name>
      <address>
        <city>Praha 5</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>192</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>034</name>
      <address>
        <city>Lisieux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>031</name>
      <address>
        <city>Nevers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>040</name>
      <address>
        <city>Bad Saarow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>052</name>
      <address>
        <city>Beckum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>049</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>051</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>056</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>242</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>249</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>247</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>041</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>045</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>054</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>244</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>058</name>
      <address>
        <city>Köthen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>043</name>
      <address>
        <city>Künzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>050</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>053</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>250</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>046</name>
      <address>
        <city>Mittweida</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>243</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>246</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>044</name>
      <address>
        <city>Stuhr-Brinkum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>060</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>062</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>061</name>
      <address>
        <city>Győr</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>262</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>260</name>
      <address>
        <city>Makó</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>266</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>064</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>264</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>265</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>263</name>
      <address>
        <city>Tatabánya</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>261</name>
      <address>
        <city>Veszprém</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>270</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>273</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>272</name>
      <address>
        <city>Pozzilli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>092</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>293</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>094</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>095</name>
      <address>
        <city>Częstochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>091</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>093</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>294</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>297</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>090</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>295</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>291</name>
      <address>
        <city>Radom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>292</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>296</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>290</name>
      <address>
        <city>Ząbkowicki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>100</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>102</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>109</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>101</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>114</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>115</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>116</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>111</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>112</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>140</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>143</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>144</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>142</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>137</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>159</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>154</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>152</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>150</name>
      <address>
        <city>Morriston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>151</name>
      <address>
        <city>Newport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <link>
    <url>https://www.vimpathcp.com/vimpat-prescribing-information.pdf?v=1491846793</url>
    <description>Product Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2007</study_first_posted>
  <results_first_submitted>December 21, 2011</results_first_submitted>
  <results_first_submitted_qc>March 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2012</results_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lacosamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started in May 2004 with subjects from Austria, Belgium, Bulgaria, Czech Republic, Finland, France, Germany, Hungary, Italy, Poland, Romania, Russia, Serbia, Spain, and United Kingdom. The primary completion date occurred in January 2011, with study completion in January 2011.</recruitment_details>
      <pre_assignment_details>Participant Flow and Baseline Characteristics refer to the Safety Set (SS).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lacosamide</title>
          <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="621"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="236"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory compliance</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons for premature termination</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lacosamide</title>
          <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="621"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing the Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).</title>
        <description>Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.</description>
        <time_frame>From entry Visit 1 through end of treatment (approximately 6.5 years)</time_frame>
        <population>This analysis includes all subjects (all 621) in the Safety Set (SS).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing the Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).</title>
          <description>Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.</description>
          <population>This analysis includes all subjects (all 621) in the Safety Set (SS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="621"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).</title>
        <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:
Is fatal
Is life-threatening
Results in persistent or significant disability/incapacity
Requires inpatient hospitalization
Prolongs existing inpatient hospitalization
Is a congenital anomaly/birth defect
Is considered to be an important medical event. Such an event may not be immediately life threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definitions above</description>
        <time_frame>From entry Visit 1 through end of treatment (approximately 6.5 years)</time_frame>
        <population>This analysis includes all subjects (all 621) in the Safety Set (SS).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).</title>
          <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:
Is fatal
Is life-threatening
Results in persistent or significant disability/incapacity
Requires inpatient hospitalization
Prolongs existing inpatient hospitalization
Is a congenital anomaly/birth defect
Is considered to be an important medical event. Such an event may not be immediately life threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definitions above</description>
          <population>This analysis includes all subjects (all 621) in the Safety Set (SS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="621"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Baseline Visit.</title>
        <description>On the Likert Scale, 0 = no pain and 10 = worst possible pain.</description>
        <time_frame>Baseline</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 620 are included in this analysis.
Data was not available for 1 subject at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Baseline Visit.</title>
          <description>On the Likert Scale, 0 = no pain and 10 = worst possible pain.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 620 are included in this analysis.
Data was not available for 1 subject at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="1.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Last Visit.</title>
        <description>On the Likert Scale, 0 = no pain and 10 = worst possible pain.</description>
        <time_frame>Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 619 are included in this analysis.
Data was not available for 2 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Last Visit.</title>
          <description>On the Likert Scale, 0 = no pain and 10 = worst possible pain.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 619 are included in this analysis.
Data was not available for 2 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" spread="2.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Pain Score as Measured by a 100 mm Visual Analog Scale (VAS) at Baseline.</title>
        <description>Visual Analog Scale (VAS) 0 mm = no pain and 100 mm = worst possible pain.</description>
        <time_frame>Baseline</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 213 are included in this analysis.
Data was not available for 408 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Score as Measured by a 100 mm Visual Analog Scale (VAS) at Baseline.</title>
          <description>Visual Analog Scale (VAS) 0 mm = no pain and 100 mm = worst possible pain.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 213 are included in this analysis.
Data was not available for 408 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.83" spread="15.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Pain Score as Measured by a 100 mm Visual Analogue Scale (VAS) at Last Visit.</title>
        <description>On VAS 0 mm = no pain and 100 mm = worst possible pain.</description>
        <time_frame>Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 214 are included in this analysis.
Data was not available for 407 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Score as Measured by a 100 mm Visual Analogue Scale (VAS) at Last Visit.</title>
          <description>On VAS 0 mm = no pain and 100 mm = worst possible pain.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 214 are included in this analysis.
Data was not available for 407 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.47" spread="23.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient’s Global Impression of Change (PGIC) at Last Visit.</title>
        <description>The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse [score of 1] to much better [score of 7]).
Reported results are presented as Better (sum of mildly, moderately, or much better), No Change, or Worse (sum of mildly, moderately, or much worse).</description>
        <time_frame>Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 551 are included in this analysis.
Data was not available for 70 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient’s Global Impression of Change (PGIC) at Last Visit.</title>
          <description>The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse [score of 1] to much better [score of 7]).
Reported results are presented as Better (sum of mildly, moderately, or much better), No Change, or Worse (sum of mildly, moderately, or much worse).</description>
          <population>Of the 621 subjects in the Safety Set (SS), 551 are included in this analysis.
Data was not available for 70 subjects at the time of this measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="551"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Intensity at Last Visit.</title>
        <description>0 = no pain and 10 = most intense pain sensation imaginable.</description>
        <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects of the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Intensity at Last Visit.</title>
          <description>0 = no pain and 10 = most intense pain sensation imaginable.</description>
          <population>Of the 621 subjects of the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Sharpness at Last Visit.</title>
        <description>0 = not sharp and 10 = most sharp sensation imaginable.</description>
        <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Sharpness at Last Visit.</title>
          <description>0 = not sharp and 10 = most sharp sensation imaginable.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Heat at Last Visit.</title>
        <description>0 = not hot and 10 = the most hot sensation imaginable.</description>
        <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Heat at Last Visit.</title>
          <description>0 = not hot and 10 = the most hot sensation imaginable.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Cold at Last Visit.</title>
        <description>0 = not cold and 10 = the coldest sensation imaginable.</description>
        <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Cold at Last Visit.</title>
          <description>0 = not cold and 10 = the coldest sensation imaginable.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Dullness at Last Visit.</title>
        <description>0 = not dull and 10 = most dull sensation imaginable.</description>
        <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Dullness at Last Visit.</title>
          <description>0 = not dull and 10 = most dull sensation imaginable.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Unpleasantness at Final Visit.</title>
        <description>0 = not unpleasant and 10 = most unpleasant sensation imaginable.</description>
        <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 193 are included in this analysis.
Data was not available for 428 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Unpleasantness at Final Visit.</title>
          <description>0 = not unpleasant and 10 = most unpleasant sensation imaginable.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 193 are included in this analysis.
Data was not available for 428 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Surface Pain at Last Visit.</title>
        <description>0 = no surface pain and 10 = most intense surface pain imaginable.</description>
        <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 193 are included in this analysis.
Data was not available for 428 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Surface Pain at Last Visit.</title>
          <description>0 = no surface pain and 10 = most intense surface pain imaginable.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 193 are included in this analysis.
Data was not available for 428 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Deep Pain at Last Visit.</title>
        <description>0 = no deep pain and 10 = most intense deep pain imaginable.</description>
        <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 193 are included in this analysis.
Data was not available for 428 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Deep Pain at Last Visit.</title>
          <description>0 = no deep pain and 10 = most intense deep pain imaginable.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 193 are included in this analysis.
Data was not available for 428 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Itchiness at Final Visit.</title>
        <description>0 = not itchy and 10 = most itchy sensation imaginable.</description>
        <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Itchiness at Final Visit.</title>
          <description>0 = not itchy and 10 = most itchy sensation imaginable.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Sensitivity at Last Visit.</title>
        <description>0 = not sensitive and 10 = most sensitive sensation imaginable.</description>
        <time_frame>Baseline Visit; Last Visit (approximately 2 years)</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) – Sensitivity at Last Visit.</title>
          <description>0 = not sensitive and 10 = most sensitive sensation imaginable.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 195 are included in this analysis.
Data was not available for 426 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Pain Interference With Sleep (11-point Likert Scale) at Baseline.</title>
        <description>0 = no interference with sleep and 10 = worst possible interference with sleep.</description>
        <time_frame>Baseline</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 620 are included in this analysis.
Data was not available for 1 subject at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Interference With Sleep (11-point Likert Scale) at Baseline.</title>
          <description>0 = no interference with sleep and 10 = worst possible interference with sleep.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 620 are included in this analysis.
Data was not available for 1 subject at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="1.850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Pain Interference With Sleep (11-point Likert Scale) at Last Visit.</title>
        <description>0 = no interference with sleep and 10 = worst possible interference with sleep.</description>
        <time_frame>Last Visit</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 619 are included in this analysis.
Data was not available for 2 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Interference With Sleep (11-point Likert Scale) at Last Visit.</title>
          <description>0 = no interference with sleep and 10 = worst possible interference with sleep.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 619 are included in this analysis.
Data was not available for 2 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="2.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Pain Interference With Activity (11-point Likert Scale) at Baseline.</title>
        <description>0 = no interference with activity and 10 = worst possible interference with activity.</description>
        <time_frame>Baseline</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 620 are included in this analysis.
Data was not available for 1 subject at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Interference With Activity (11-point Likert Scale) at Baseline.</title>
          <description>0 = no interference with activity and 10 = worst possible interference with activity.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 620 are included in this analysis.
Data was not available for 1 subject at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11" spread="1.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Pain Interference With Activity (11-point Likert Scale) at Last Visit.</title>
        <description>0 = no interference with activity and 10 = worst possible interference with activity.</description>
        <time_frame>Last Visit</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 619 are included in this analysis.
Data was not available for 2 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Interference With Activity (11-point Likert Scale) at Last Visit.</title>
          <description>0 = no interference with activity and 10 = worst possible interference with activity.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 619 are included in this analysis.
Data was not available for 2 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="2.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Quality of Life Using the SF-36 Health Survey – Physical Component Summary (PCS) at Baseline.</title>
        <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
        <time_frame>Baseline</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 588 are included in this analysis.
Data was not available for 33 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Quality of Life Using the SF-36 Health Survey – Physical Component Summary (PCS) at Baseline.</title>
          <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 588 are included in this analysis.
Data was not available for 33 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Quality of Life Using the SF-36 Health Survey – Physical Component Summary (PCS) at Last Visit.</title>
        <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
        <time_frame>Last Visit</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 552 are included in this analysis.
Data was not available for 69 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Quality of Life Using the SF-36 Health Survey – Physical Component Summary (PCS) at Last Visit.</title>
          <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 552 are included in this analysis.
Data was not available for 69 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Quality of Life Using the SF-36 Health Survey – Mental Component Summary (MCS) at Baseline.</title>
        <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
        <time_frame>Baseline</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 588 are included in this analysis.
Data was not available for 33 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Quality of Life Using the SF-36 Health Survey – Mental Component Summary (MCS) at Baseline.</title>
          <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 588 are included in this analysis.
Data was not available for 33 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" spread="11.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Quality of Life Using the SF-36 Health Survey – Mental Component Summary (MCS) at Last Visit.</title>
        <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
        <time_frame>Last Visit</time_frame>
        <population>Of the 621 subjects in the Safety Set (SS), 552 are included in this analysis.
Data was not available for 69 subjects at the time of this measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide</title>
            <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Quality of Life Using the SF-36 Health Survey – Mental Component Summary (MCS) at Last Visit.</title>
          <description>The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.</description>
          <population>Of the 621 subjects in the Safety Set (SS), 552 are included in this analysis.
Data was not available for 69 subjects at the time of this measurement.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected from Entry Visit 1 through End of Treatment (Approximately 6.5 Years).</time_frame>
      <desc>Adverse Events refer to the Safety Set (SS). SS includes all subjects that were administered the investigational products at least once.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lacosamide</title>
          <description>50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Perforated ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Bronchitis fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>QRS axis abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Toe deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Pleural mesothelioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Epithelioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Drop attacks</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Apallic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Brain stem syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosomatic disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Neuropathic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Diabetic macroangiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="44" subjects_affected="34" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="63" subjects_affected="49" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="41" subjects_affected="31" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="49" subjects_affected="45" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="45" subjects_affected="38" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="45" subjects_affected="40" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>UCB has &gt; 60 but &lt;= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB (Study Director)</name_or_title>
      <organization>UCB Clinical Trial Call Center</organization>
      <phone>1-887-822-9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

